After a dismal Q3 '25 results and YTD performance, the main question is whether Alexandria Real Estate Equities, Inc. (NYSE: ARE ), a biotech lab/office REIT, will rebound, or whether it has at least reachedBashar is a contributing writer at Seeking Alpha, focusing on Long/Short investment ideas, with a geographic focus in North America. Before that, Bashar worked at an Investment Fund in the United Kingdom. He has a Master's degree in Finance from the Queen Mary University of London and a Bachelor's degree ...